Insider Selling: Epizyme major shareholder Sells 366,666 Shares of Stock (EPZM)
Epizyme (NASDAQ:EPZM) major shareholder Bay City Capital Llc unloaded 366,666 shares of Epizyme stock on the open market in a transaction dated Monday, August 25th. The stock was sold at an average price of $33.98, for a total transaction of $12,459,310.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Epizyme (NASDAQ:EPZM) traded up 6.97% on Monday, hitting $35.92. The stock had a trading volume of 539,956 shares. Epizyme has a 52-week low of $18.10 and a 52-week high of $42.71. The stock has a 50-day moving average of $32.25 and a 200-day moving average of $27.33. The company’s market cap is $1.206 billion.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $7.59 million. On average, analysts predict that Epizyme will post $-1.62 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on EPZM shares. Analysts at HC Wainwright raised their price target on shares of Epizyme from $40.00 to $45.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Epizyme from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 7th. They now have a $36.80 price target on the stock. Finally, analysts at Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday, July 15th. They set a “buy” rating and a $40.00 price target on the stock.
Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.